𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia

✍ Scribed by H. T. Hassan; L. E. Zyada; M. H. Ragab; J. K. H. Rees


Publisher
Springer
Year
1991
Tongue
English
Weight
681 KB
Volume
41
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis


Differentiation inducing agents in double and triple combinations can induce differentiation in primary culture of more than 80% of blast cells from some AML patients. In the present study, the interactions between these differentiating agents have been analysed using Berenbaum's general algebraic solution and three new, potentially clinically useful synergistic combinations: have been identified all trans retinoic acid (RA) + hexamethylene bisacetamide (HMBA), cytosine arabinoside (Ara-C) + HMBA and RA + Ara-C + HMBA. A measure of the effectiveness of these combinations was that the doses of Ara-C and HMBA required to induce 50% differentiation were decreased about 10-fold and 5-fold, respectively, in combination with 1 microM RA. The new synergistic combinations are important not only to limit toxicity but also because multiple drug combinations may better overcome the inherent molecular heterogeneity of the differentiation defect in AML patients. They warrant clinical trial in AML patients who are either unsuitable for or are unresponsive to conventional cytotoxic chemotherapy.


πŸ“œ SIMILAR VOLUMES


Clofarabine in the treatment of poor ris
✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

Oral idarubicin in the treatment of acut
✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per

Effect of cloretazine (VNP40101M) on acu
✍ Karen L. Morris; Julie A. Adams; John A. Liu Yin πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 612 KB

We have investigated the effect of cloretazine (VNP40101M or Laromustine), a novel sulfonylhydrazine alkylating agent with significant antileukaemic activity, alone, or combined with cytarabine or daunorubicin, on the proliferation, viability and apoptosis of cell lines and acute myeloid leukaemia b